Japan office's performance report since its 1st anniversary

In 2016 CRScube opened its office in Japan, and it is now celebrating its 1st anniversary as 'CRScube APAC K.K.', providing the best customer support to its clients in Japan.  During the first 3-years of operation, cubeCDMS® (EDC) was licensed and used for a pivotal clinical trial and received PMDA approval.  With the news of the PMDA approval of that study, interest in CRScube solutions from pharmaceutical companies and CRO has greatly increased in 2020 and 2021.

As we are wrapping up 2021 and looking back, this year has been a challenge due to COVID-19 similar to 2020.  The unprecedented global health crisis has affected all parts of society and changed how we live and work. With the Omicron variant becoming the dominant strain, it's clear returning to normal is not around the corner anytime soon.  However, the pharmaceutical, Biotech, Global Health, and Clinical Research Organizations that CRScube closely works with are continuing to move forward, spearheading a new path.

The table provides a timeline and number of studies by Phase in Japan. 

Table 1 Annual number of studies by phase

Interest and inquiries for CRScube solutions for late phase studies increased sharply in 2021 and usage of our solutions in clinical trials has increased substantially.

Table 2 CRScube solutions performance

By analyzing each solution that was licensed, in 2021, cubeCDMS® saw the biggest increase, followed by cubeIWRS® (Full) and cubeCTMS®. Moreover, the number of inquiries regarding cubeTMF® and cubeSAFETY® has also seen an increase.  Additionally, the latest version of cubeCONSENT® is planned for release in the 1st quarter of 2022, already leading to a lot of inquiries from our clients in Japan.

Contact: help_japan@crscube.io